[Clorgyline and Lilly 51641 suppression of the withdrawal syndrome induced by naloxone in morphine-dependent mice].
D000818:Animals; D003010:Clorgyline / Q000627:therapeutic use*; D003521:Cyclopropanes / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D051379:Mice; D008996:Monoamine Oxidase Inhibitors / Q000627:therapeutic use*; D009021:Morphine Dependence / Q000188:drug therapy*; D009270:Naloxone / Q000009:adverse effects* / Q000627:therapeutic use; D010647:Phenyl Ethers / Q000627:therapeutic use; D011437:Propylamines / Q000627:therapeutic use*; D013375:Substance Withdrawal Syndrome / Q000139:chemically induced / Q000188:drug therapy*
D003521:Cyclopropanes; D008996:Monoamine Oxidase Inhibitors; D010647:Phenyl Ethers; D011437:Propylamines; D009270:Naloxone; D003010:Clorgyline
Supresión por clorgilina y Lilly 51641 del síndrome de retirada inducido por naloxona en ratones dependientes de morfina.